When a woman notices her frontal hairline creeping backward month by month, accompanied by thinning eyebrows or pale, smooth skin where terminal hair used to grow, the emotional impact is profound. Often occurring around or after menopause, this distinct form of hair loss is called Frontal Fibrosing Alopecia (FFA).

First recognized in Australia by Dr. Steven Kossard in 1994, FFA was once considered rare. Today, dermatologists worldwide describe an "emerging epidemic" of FFA. Despite rising prevalence, misconception remains rampant: patients are often misdiagnosed with typical female pattern baldness, told to buy over-the-counter hair vitamins, or promised that lost hairline hair will regrow with minoxidil.

This evidence-based review clarifies the biological reality of FFA, evaluates off-label medical treatments, analyzes the controversial sunscreen association, examines hair transplant failure rates, outlines diagnostic workup steps, and provides a clear differential for patients of all skin tones.

Direct Answer: What You Need to Know First

Frontal Fibrosing Alopecia is a primary cicatricial (scarring) alopecia considered a clinical variant of Lichen Planopilaris (LPP). The immune system erroneously attacks hair follicle stem cells in the bulge region, destroying the follicle and replacing it with fibrous scar tissue.

Will the lost hair grow back? No. Once a hair follicle is fibrosed and replaced by scar tissue, hair regrowth is biologically impossible. The explicit goal of medical therapy is disease stabilization—arresting further recession—rather than reversing past loss.
Who gets FFA? Over 85% to 90% of affected patients are postmenopausal women (average onset around age 56 to 60), though premenopausal women and men can also develop the condition. Eyebrow loss precedes hairline recession in up to 80% of patients, and complete eyebrow loss occurs in 64% to 94% of cases.
Do sunscreens cause FFA? Epidemiological case-control studies and a 9-study meta-analysis (Kam et al., 2023) show a statistical association, with sunscreen and leave-on facial product users having roughly 3 times higher odds (OR ~3.02) of developing FFA. However, dermatologists stress that association does not equal causation. Sunscreen avoidance is not a validated cure, and stopping broad-spectrum sun protection increases skin cancer risks.
Which treatments actually stop the recession? No treatment is FDA-approved specifically for FFA. The best-supported medical therapies are 5-alpha-reductase inhibitors (oral finasteride or dutasteride) and intralesional steroid injections (triamcinolone acetonide). In the landmark 355-patient multicenter cohort (Vaño-Galván et al., 2014), all 111 patients treated with 5-alpha-reductase inhibitors responded—53% stabilized and 47% improved—and a 2019 treatment review (Ho & Shapiro) ranks these agents among the highest-response therapies at about 88% positive response.
Can you get a hair transplant to fix the hairline? Hair transplantation into FFA-affected scar tissue carries a high long-term failure rate. Long-term follow-up data (Vaño-Galván et al., 2019, n=51) show graft survival drops from 87% at 1 year down to just 41% at 5 years due to persistent subterranean inflammation.
How is FFA different from traction alopecia or pattern loss? Traction alopecia preserves the "fringe" of soft hair along the margin and responds to tension release. Androgenetic alopecia is non-scarring and retains follicular orifices. FFA shows loss of follicular orifices, peri-follicular erythema/scaling, facial papules, and total eyebrow loss.

What Is Frontal Fibrosing Alopecia, and Who Gets It?

Frontal Fibrosing Alopecia is characterized by symmetrical, band-like recession of the frontal and temporal hairline. As the hairline recedes, it exposes a strip of pale, smooth, shiny skin that lacks normal follicular openings ("pores").

                     CLINICAL ANATOMY OF FFA
                     
     Receded Hairline Band (Smooth, Pale Scarred Skin)
   ══════════════════════════════════════════════════════
    *   *   *   "Lonely Hairs" (Isolated Surviving Follicles)
   ──────────────────────────────────────────────────────
       ▲   ▲    Perifollicular Erythema & Keratotic Scaling
       │   │    (Active Lymphocytic Inflammation)
   
   Eyebrow Loss (64%–94% of cases, often precedes hairline)
   Facial Papules (Rough yellow/flesh-colored facial bumps)

The Pathophysiology of Scarring

Targeting the Bulge: Lymphocytic T-cells target the bulge region of the hair follicle—the anatomical reservoir housing hair follicle stem cells.
Collapse of Immune Privilege: Under normal conditions, hair follicles maintain "immune privilege" (suppressing immune cell activity). In FFA, this privilege collapses, allowing CD8+ cytotoxic T-cells to attack the follicular epithelium.
Peroxisome Proliferator-Activated Receptor (PPAR-γ) Loss: Molecular profiling reveals a severe loss of PPAR-gamma receptor signaling in the sebaceous gland and bulge region. This loss impairs lipid metabolism, leading to follicular inflammation, sebaceous gland collapse, and irreversible fibrosis.
Irreversible Fibrosis: Once stem cells in the bulge are destroyed, the follicle can no longer enter a new anagen (growth) cycle. The follicular structure collapses and is replaced by a column of dense fibrous scar tissue.

Characteristic Clinical Features

Eyebrow Loss (Madarosis): Partial or complete eyebrow thinning occurs in 64% to 94% of patients, often years before hairline recession becomes noticeable.
The "Lonely Hair" Sign: Isolated, individual terminal hairs surviving inside the broad band of smooth, scarred forehead skin.
Perifollicular Erythema & Scaling: Redness and fine flaking around active hair follicles at the leading edge of the receding hairline—a key sign of ongoing inflammation.
Facial Papules: Non-inflammatory, flesh-colored or yellowish papules on the facial skin (especially temples and cheeks), representing lichen planopilaris involvement of facial vellus hair follicles.
Loss of Body Hair: Loss of arm, leg, axillary, or pubic hair occurs in 25% to 50% of patients.

Diagnostic & Staging Workup: Dermoscopy & Biopsy

Accurate diagnosis of FFA requires evaluating both clinical signs and specialized diagnostic tools:

1. Trichoscopy (Dermoscopy of Scalp)

Dermatologists use a dermatoscope to inspect the leading edge of the receding hairline:

Absence of Follicular Openings: The receded band shows complete loss of follicular ostia, appearing as smooth, ivory-white skin.
Perifollicular Keratosis & Erythema: Tubular white scales wrapping around individual hair shafts at the active margin, accompanied by a pinkish-red inflammatory halo.
Targetoid Pigmentation: In skin of color, perifollicular hyperpigmentation (dark rings around follicles) is a prominent trichoscopic marker of active disease.

2. Scalp Biopsy Protocol

When clinical features are equivocal, a 4 mm punch biopsy is performed:

Location: Taken from an active, inflamed, scaling follicle at the leading hairline edge—never from the smooth, fully scarred central forehead skin.
Histopathology: Shows a lichenoid lymphocytic infiltrate concentrated around the infundibulum and isthmus (bulge area) of the follicle, accompanied by concentric perifollicular fibrosis and destruction of the sebaceous glands.

3. Disease Activity Scoring (LPPAI)

Clinicians track treatment efficacy using the Lichen Planopilaris Activity Index (LPPAI), which scores symptoms (pruritus, pain, burning), clinical signs (erythema, end-stage scarring, perifollicular scale), and spreading speed.

Will the Hair That Is Lost Grow Back?

Understanding the fundamental biological difference between non-scarring alopecia and scarring alopecia is essential for patient expectations:

            NON-SCARRING VS SCARRING ALOPECIA PROGNOSIS
            
  Non-Scarring (Androgenetic / Areata / Telogen)
  ┌──────────────────────────────────────────────────────────┐
  │ Follicle Intact ──► Miniature / Dormant ──► Reversible   │
  └──────────────────────────────────────────────────────────┘
  
  Scarring Alopecia (Frontal Fibrosing Alopecia / LPP)
  ┌──────────────────────────────────────────────────────────┐
  │ Bulge Stem Cells Destroyed ──► Fibrotic Scar ──► PERMANENT│
  └──────────────────────────────────────────────────────────┘

In Non-Scarring Loss: As detailed in our guides on androgenetic alopecia medical treatment and telogen effluvium recovery, hair follicles shrink (miniaturize) or enter resting phases, but the stem cell reservoir remains alive. Treatments like minoxidil, finasteride, or low-level light therapy can reactivate dormant follicles.
In FFA (Scarring Loss): Once the follicular orifice disappears and smooth scar tissue forms, the follicle is dead. No topical serum, oral vitamin, laser cap, or plasma injection can regenerate a destroyed follicle.
Defining Success: Successful FFA management means stopping the recession line in its tracks. If a patient retains their current hairline for 2 to 5 years without further backward movement, treatment is a clinical success.

Do Sunscreens and Facial Products Cause Frontal Fibrosing Alopecia?

One of the most intense debates in modern dermatology is the potential role of daily leave-on facial sunscreens and cosmetics in triggering or accelerating FFA.

                  THE SUNSCREEN & FACIAL PRODUCT DATA
                  
   Kam et al. (2023) 9-Study Meta-Analysis (1,248 cases / 1,459 controls):
   ┌─────────────────────────────────────────────────────────────┐
   │ Use of Sunscreen / Leave-On Facial Cosmetics                │
   │ Pooled Odds Ratio = 3.02 (95% CI: 1.67 – 5.47)              │
   └─────────────────────────────────────────────────────────────┘
   
   Critical Dermatologic Interpretation:
   • Statistical Association ≠ Direct Biological Causation
   • FFA patients have sensitive facial skin / facial papules ──► Use MORE products
   • Mineral Sunscreens (Zinc/Titanium) carry NO chemical allergen risk
   • STOPPING SUNSCREEN IS NOT RECOMMENDED BY AAD OR BAD

The Evidence

The 3-Fold Odds Ratio: A systematic review and meta-analysis of 9 case-control studies covering 1,248 FFA patients and 1,459 controls published by Kam et al. (2023) confirmed a significant association between FFA and regular sunscreen use, with a pooled Odds Ratio (OR) of 3.02 (95% CI: 1.67–5.47). Similar associations were identified for general leave-on facial moisturizers (OR ~2.2).
Proposed Hypotheses: Researchers have hypothesized that chemical sunscreen active ingredients (such as avobenzone, octocrylene, or oxybenzone) or cosmetic nanoparticles (like titanium dioxide) might act as photo-allergens or endocrine disruptors, triggering a lichenoid immune response in genetically susceptible individuals.
The Reverse Causality Counter-Argument: Leading dermatologists note that reverse causality is highly probable. Patients developing early, undiagnosed FFA experience facial burning, perifollicular redness, and facial papules, prompting them to apply more facial creams, soothing moisturizers, and daily sunscreens than unaffected controls.
Actionable Clinical Guidance: Neither the American Academy of Dermatology (AAD) nor the British Association of Dermatologists (BAD) recommends stopping sun protection. Dermatologists suggest switching from chemical sunscreens to pure mineral (physical) sunscreens containing non-nano zinc oxide or titanium dioxide, avoiding fragranced leave-on facial products, and continuing daily sun protection.

Which Treatments Actually Work: Finasteride, Dutasteride, or Steroids?

Because no drug holds an official FDA approval for Frontal Fibrosing Alopecia, treatments are prescribed off-label based on observational cohort studies, international consensus guidelines, and small clinical trials.

              FFA TREATMENT RESPONSE EFFICACY LADDER
              
   Therapy                                    Stabilization / Response (%)
   ──────────────────────────────────────────────────────────────────────
   Oral Dutasteride / Finasteride (5-ARIs)   ▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓  ~88% Positive Response
   Intralesional Triamcinolone (IL TAC)      ▓▓▓▓▓▓▓▓▓▓▓▓▓      60.0% – 70.0%
   Oral Hydroxychloroquine (6-Month Course)  ▓▓▓▓▓▓▓▓▓▓▓▓▓▓     73.0% (LPPAI drop)
   Oral Pioglitazone (PPAR-γ Agonist)        ▓▓▓▓▓▓▓▓▓▓▓        50.0% – 65.0%
   Oral JAK Inhibitors (Tofacitinib/Baricitinib) ▓▓▓▓▓▓▓▓▓▓▓▓   60.0% – 75.0%
   Topical Calcineurin Inhibitors (Tacrolimus)▓▓▓▓▓▓▓▓▓        40.0% – 50.0%
   Platelet-Rich Plasma (PRP) / Laser Caps   ░░                 Unproven / Weak

1. 5-Alpha-Reductase Inhibitors (Dutasteride & Finasteride)

Despite FFA being a lymphocytic immune condition, 5-alpha-reductase inhibitors (5-ARIs) represent the single most effective systemic therapy for halting hairline recession.

Mechanism: 5-ARIs block the conversion of testosterone to dihydrotestosterone (DHT). DHT is believed to modulate neurogenic inflammation and perifollicular immune activation in the hairline.
Evidence: In the world's largest multicenter FFA retrospective cohort (355 patients published by Vaño-Galván et al., 2014), the 111 patients treated with oral 5-ARIs showed a 100% response rate—53% stabilized and 47% improved—and a later treatment review (Ho & Shapiro, 2019) ranks 5-ARIs among the highest-response therapies at roughly 88% positive response. Oral dutasteride (0.5 mg daily to weekly) demonstrated superior efficacy compared to oral finasteride (2.5 mg to 5 mg daily).
Consensus: The 2024 International SOFFIA Consensus and 2026 expert guidelines rank oral dutasteride as first-line systemic therapy for postmenopausal FFA patients.

2. Intralesional Corticosteroids (Triamcinolone Injections)

Protocol: Triamcinolone acetonide (TAC) injected directly into active, red, scaling hairline margins.
Dosing: 2.5 mg/mL to 5 mg/mL, injected in 0.1 mL micro-droplets spaced 0.5 cm to 1.0 cm apart along the receding front, repeated every 4 to 12 weeks.
Efficacy: Highly effective at eliminating local burning, itching, and perifollicular erythema, achieving active disease control in 60% to 70% of patients. Also used for eyebrow preservation.

3. Oral Hydroxychloroquine (Antimalarial Immunomodulator)

Mechanism: Inhibits antigen presentation and reduces lymphocytic inflammatory signaling.
Evidence: Reduces Lichen Planopilaris Activity Index (LPPAI) scores in 73% of patients after 6 months of therapy. However, systemic use requires baseline and periodic ophthalmologic screening for retinal toxicity.

4. Oral Pioglitazone (PPAR-γ Agonist)

Mechanism: Pioglitazone is a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist originally approved for type 2 diabetes. By restoring lost PPAR-γ signaling in the follicle, it targets the core metabolic deficit driving follicular scarring.
Evidence: Small open-label studies show 50% to 65% stabilization in refractory FFA, though side effects (weight gain, edema) require monitoring.

5. Emerging Oral JAK Inhibitors (Tofacitinib & Baricitinib)

Mechanism: Janus kinase (JAK) inhibitors block IFN-gamma and IL-15 signaling pathways involved in autoimmune hair follicle destruction.
Evidence: Small case series in refractory Lichen Planopilaris and FFA demonstrate 60% to 75% inflammatory stabilization, though high drug costs and lack of FDA approval limit broad first-line use.

Treatment Option	Dosing / Route	Primary Target	Stabilization Rate	Key Safety Considerations
Oral Dutasteride / Finasteride (5-ARIs)	Dutasteride 0.5 mg daily–weekly; Finasteride 2.5–5 mg daily	Systemic 5-AR inhibition	~88% positive response (53% stabilize / 47% improve)	Off-label; dutasteride superior to finasteride; pregnancy Category X
Intralesional TAC	2.5 – 5.0 mg/mL micro-inj	Leading-edge inflammation	60% – 70%	Risk of localized cutaneous atrophy
Tacrolimus 0.1%	Topical ointment BID	Eyebrows & facial papules	40% – 50%	Transient burning sensation upon application
Hydroxychloroquine	200 mg BID oral	Systemic immune suppression	73% (Activity drop)	Annual retinal screening mandatory
Oral Pioglitazone	15 mg to 30 mg daily	PPAR-γ receptor restoration	50% – 65%	Weight gain, fluid retention, ankle edema
Oral Tofacitinib	5 mg BID oral	JAK1/3 pathway blockade	60% – 75%	Off-label, high cost, lab monitoring needed

4-Step Clinical Treatment Workflow

To navigate diagnosis, medical stabilization, and long-term maintenance, dermatologists utilize a 4-step management matrix:

                  4-STEP FFA MANAGEMENT WORKFLOW
                  
   Step 1: Diagnostic Confirmation & Baseline Measurement
   ┌─────────────────────────────────────────────────────────────┐
   │ Perform trichoscopy; take hairline photographs from 5 angles│
   │ Perform 4 mm punch biopsy if features overlap with CCCA     │
   └─────────────────────────────────────────────────────────────┘
                                │
                                ▼
   Step 2: Initiate First-Line Medical Stabilization
   ┌─────────────────────────────────────────────────────────────┐
   │ Postmenopausal: Oral Dutasteride 0.5 mg + IL-TAC injections │
   │ Premenopausal: Topical Tacrolimus + Spironolactone / Clobetasol│
   └─────────────────────────────────────────────────────────────┘
                                │
                                ▼
   Step 3: Monitor Activity & Refractory Escalation
   ┌─────────────────────────────────────────────────────────────┐
   │ Re-evaluate hairline position and LPPAI score every 3–6 mos  │
   │ If active: Add Oral Hydroxychloroquine or Oral Pioglitazone  │
   └─────────────────────────────────────────────────────────────┘
                                │
                                ▼
   Step 4: Cosmetic Reconstruction & Long-Term Maintenance
   ┌─────────────────────────────────────────────────────────────┐
   │ Eyebrow microblading after disease quiescence is achieved   │
   │ Hair transplant ONLY after 2+ years of strict stability     │
   └─────────────────────────────────────────────────────────────┘

Can a Hair Transplant Restore a Hairline Lost to FFA?

For patients with extensive hairline recession, a hair transplant (FUE or FUT) appears to be an attractive option. However, hair transplantation in Frontal Fibrosing Alopecia carries severe long-term caveats.

                   FFA HAIR TRANSPLANT GRAFT SURVIVAL
                   
   Graft Survival Rate Over Time (Vaño-Galván et al., 2019, n = 51)
   
   1 Year Post-Op  ▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓  87.0% Survival
   3 Years Post-Op ▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓                   58.0% Survival
   5 Years Post-Op ▓▓▓▓▓▓▓▓▓▓▓                           41.0% Survival (59% Failed)

The Evidence: Why Transplants Fail Long-Term

As highlighted in our comparison of FUE vs FUT hair transplants, transplanting hair into healthy scalp yields 90%+ long-term graft survival. In FFA, the biological environment is completely different.

In a landmark multi-center study of 51 FFA patients undergoing hair transplantation (Vaño-Galván et al., 2019):

Initial Success: At 1 year post-procedure, graft survival was acceptable at 87%.
Long-Term Loss: By 3 years, survival fell to 58%. By 5 years post-transplant, graft survival plummeted to 41%—meaning nearly 60% of transplanted hair grafts were destroyed.
The Pathomechanism: Even when the scalp appears clinically quiescent, low-grade T-cell lymphocytic inflammation persists deep around vascular structures, eventually attacking the newly transplanted donor follicles.
Transplant Selection Rules: Surgical hairline restoration should only be considered after at least 1 to 2 years of strict, documented disease stability on medical therapy, and patients must be warned that long-term graft survival is guarded.

How Is FFA Different from Androgenetic, Traction, or CCCA Hair Loss?

Differential diagnosis is vital because treatments for non-scarring hair loss (like minoxidil) or traction hair loss (like tension release) fail to stop scarring in FFA.

                    HAIRLINE DIFFERENTIAL DIAGNOSIS
                    
   Condition                     Key Distinguishing Features
   ─────────────────────────────────────────────────────────────────────────────
   Frontal Fibrosing Alopecia    Loss of pores, lonely hairs, eyebrow loss,
                                 perifollicular scaling, facial papules.
   Traction Alopecia             Fringe sign preserved (soft hair along edge),
                                 history of tight braids/weaves, no eyebrow loss.
   Androgenetic Alopecia         Pores intact, diffuse thinning behind hairline,
                                 miniaturized hairs present, no scarring.
   Central Centrifugal (CCCA)    Starts on crown/vertex (Black women), painful,
                                 can co-occur with FFA in skin of color.

1. Traction Alopecia

As detailed in our guide on traction alopecia edge recovery, traction alopecia is driven by mechanical hairstyle tension.

The Fringe Sign: Traction alopecia preserves a fine "fringe" of short, soft vellus hairs right along the outermost edge of the frontotemporal hairline. In FFA, this fringe is lost, leaving a sharp, stark line between smooth forehead skin and terminal scalp hair.
Eyebrows: Eyebrows are completely unaffected in traction alopecia.

2. Central Centrifugal Cicatricial Alopecia (CCCA) & Skin of Color Nuances

CCCA is a primary scarring alopecia occurring predominantly in Black women.

Anatomical Origin: CCCA originates at the vertex or crown of the scalp and expands centrifugally outward. FFA begins at the frontal and temporal hairline.
Overlap in Skin of Color: As emphasized in dermatologic literature (Ramos et al., 2021), FFA is increasingly recognized in Black women, where it can be misdiagnosed as traction alopecia or co-exist alongside CCCA. In darker skin types, perifollicular hyperpigmentation (dark halos around follicles) often replaces the typical erythema seen in lighter skin.

3. Alopecia Areata

As covered in our overview of alopecia areata and JAK inhibitors, alopecia areata is a non-scarring autoimmune disease featuring smooth, round patches. Unlike FFA, follicles remain alive and hair can fully regrow under targeted therapy.

The Role of Menopause and Hormonal Health

FFA clusters overwhelmingly in postmenopausal women around age 60. As detailed in our breakdown of menopause skin changes and aesthetic options, the steep decline in circulating estrogen relative to local tissue androgens alters follicular immune privilege and accelerates hairline recession.

Hormone replacement therapy (HRT) alone has not been proven to stop FFA progression, which is why targeted 5-alpha-reductase inhibition remains necessary regardless of HRT status.

Cosmetic Camouflage & Eyebrow Reconstruction Rules

Because lost hair will not regrow, managing appearance is crucial for psychological well-being:

Eyebrow Microblading & Tattooing: Eyebrow microblading is an effective way to restore eyebrow appearance. However, microblading introduces skin trauma that can trigger a Koebner phenomenon (reactivating FFA inflammation) if performed during active disease. Dermatologists insist that microblading be performed only after at least 6 months of documented disease quiescence.
Hairstyle Modifications: Soft bangs or side-swept styles can camouflage hairline recession without placing mechanical tension on active follicles.
Facial Papule Management: Facial papules (yellowish bumps on temples) respond well to oral isotretinoin (low-dose 10 mg daily) or topical retinoids.
Low-Dose Oral Minoxidil Adjunct: While minoxidil cannot resurrect destroyed follicles in the receded band, low-dose oral minoxidil (0.625 mg to 1.25 mg daily) is frequently combined with 5-ARIs to thicken non-scarred hair behind the leading edge and combat co-existing androgenetic thinning.

FAQs

Is frontal fibrosing alopecia reversible?

No. FFA is a scarring alopecia. Once hair follicles are destroyed and replaced by scar tissue, the hair cannot regrow. Successful treatment means arresting further recession so that your current hairline is preserved.

Should I stop wearing sunscreen if I have FFA?

No. Leading international dermatology guidelines explicitly advise against stopping sun protection. While studies show a statistical association between sunscreen use and FFA, association is not causation. Switch to a pure mineral sunscreen (zinc oxide or titanium dioxide) without added fragrances.

Does frontal fibrosing alopecia affect Black women?

Yes. While historically described in Caucasian women, FFA is increasingly diagnosed in Black women and patients of darker skin tones. In skin of color, eyebrow loss and perifollicular dark spots (hyperpigmentation) along the hairline are key early warning signs often mistaken for traction alopecia.

Can eyebrow microblading trigger FFA flare-ups?

Yes, if performed while the disease is active. Microblading creates micro-incisions in the dermis, which can trigger a Koebner reaction (inflammatory flare). Patients should wait until their dermatologist confirms complete disease quiescence before undergoing microblading.

Do laser caps or LLLT work for FFA?

As evaluated in our evidence review of FDA-cleared laser caps for hair loss, low-level light therapy is designed for non-scarring androgenetic alopecia. It has limited evidence in scarring alopecias like FFA and cannot regenerate destroyed follicles.

How long do I need to stay on dutasteride or finasteride for FFA?

FFA is a chronic, long-term condition. Medical therapy with oral dutasteride or finasteride is typically continued for 3 to 5 years or until the disease enters spontaneous burnt-out quiescence, under regular dermatologic supervision.

Sources

StatPearls [Internet]: Porriño-Bustamante ML, Fernández-Pugnaire MA, Arias-Santiago S. Frontal Fibrosing Alopecia. NCBI Bookshelf. Last updated June 12, 2024. Available from: ncbi.nlm.nih.gov/books/NBK519001/
Journal of the American Academy of Dermatology: Vaño-Galván S, et al. Frontal fibrosing alopecia: a multicenter review of 355 patients. J Am Acad Dermatol. 2014;70(4):670-678. PMID: 24508293
Journal of Cosmetic Dermatology: Kam J, et al. Sunscreen and personal care product use in frontal fibrosing alopecia: A systematic review and meta-analysis. J Cosmet Dermatol. 2023;22(7):1982-1991. PMID: 37014396
Journal of the American Academy of Dermatology: Vaño-Galván S, et al. Hair transplantation in frontal fibrosing alopecia: A multicenter review of 51 patients. J Am Acad Dermatol. 2019;81(3):865-866. PMID: 31350039
Dermatologic Therapy: Ho A, Shapiro J. Medical therapy for frontal fibrosing alopecia: A review and clinical guide. Dermatol Ther. 2019;32(3):e12842. PMID: 30953702
Journal of Clinical Medicine: Saceda-Corralo D, et al. The FFA treatment dilemma: A comprehensive review of emerging and consensus therapies. J Clin Med. 2024;13(8):2263. PMCID: PMC11012663
Dermatology Practical & Conceptual: Saber M, et al. Comparison of finasteride versus hydroxychloroquine in frontal fibrosing alopecia: A randomized clinical trial. Dermatol Pract Concept. 2024;14(1):e2024018. PMID: 37691183
DermNet NZ: Frontal fibrosing alopecia clinical overview. Available from: dermnetnz.org/topics/frontal-fibrosing-alopecia

Frontal Fibrosing Alopecia: Treatments, Regrowth Reality, and the Sunscreen Link